News Story: Full Text
Sponsored By
Gamma Tiles
Please Click On The Above Banner For More Details
Braintumor Website


Novel use of Gliadel for gliomas

Posted on: 05/24/2002

Novel use of Gliadel for gliomas

Allan H Friedman, Sunil Agarwal, Brandon Evans, Amy Walker, Sandra Tourt-Uhlig, David Reardon, Mary L Affronti, Deborah Allen, Rodney Beason, Sridharan Gururangan, Susanne Jackson, Roger McLendon, Jennifer Quinn, Jeremy Rich, John Sampson, Valerie Stafford-Fox, Karen Ziegler, Darell D Bigner, Henry Friedman, Duke University Medical Center, Durham, NC; Guilford Pharmaceuticals, Baltimore, MD; Pharmacia & Upjohn, Kalamazoo, MI; Schering-Plough, Kenilworth, NJ.

The Brain Tumor Center at Duke is conducting three trials utilizing Gliadel for the treatment of high-grade and low-grade gliomas. Two trials are currently being used for malignant glioma. A phase II trial of Gliadel plus temozolomide is being evaluated in patients with recurrent malignant glioma. Patients undergo surgical resection and placement of Gliadel wafers followed by temozolomide at a dose of 200 mg/m2/day for 5 days with cycles repeated every 4 weeks. Eight patients have been accrued to date with the following progression free survival: 48+, 36+, 24, 20+, 16, and 16 weeks, respectively. One patient refused therapy after 2 cycles. One patient was removed from study due to home physician advice. The second protocol, for patients with recurrent malignant glioma, is a phase I trial of Gliadel plus CPT-11. Patients undergo surgical resection with placement of Gliadel wafers followed by CPT-11 administered weekly x 4 with a 2 week rest. Thirteen patients have been accrued to date with the highest CPT-11 dose to date 100 mg/m2. The third protocol is a phase II trial of Gliadel for patients with recurrent low-grade glioma. Seven patients have been treated to date with the following progression free survivals: 40+, 36+, 26+, 27, 15, 7, and 4 months, respectively. In summary, this trial is building on the known anti-glioma activity of Gliadel with new multi-modality treatment strategies.

Source: ASCO 2002
Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557